Details for Patent: 9,040,559
✉ Email this page to a colleague
Title: | BETA2-adrenoceptor agonists |
Abstract: | Compounds of formula ##STR00001## in free or salt or solvate form, where Ar is a group of formula ##STR00002## Y is carbon or nitrogen and R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7, R.sup.8, R.sup.9, R.sup.10, X, n, p, q and r are as defined in the specification, their preparation and their use as pharmaceuticals, particularly for the treatment of obstructive or inflammatory airways diseases. |
Inventor(s): | Cuenoud; Bernard (Horsham, GB), Bruce; Ian (Horsham, GB), Fairhurst; Robin Alec (Horsham, GB), Beattie; David (Horsham, GB) |
Assignee: | Novartis AG (Basel, CH) |
Filing Date: | Aug 04, 2014 |
Application Number: | 14/450,692 |
Claims: | 1. A capsule that contains a pharmaceutical composition comprising: (A) (R)-5-[2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-1H-quin- olin-2-one or a salt or solvate thereof; (B) an anticholinergic or antimuscarinic agent; and (C) a pharmaceutically acceptable carrier. 2. A capsule according to claim 1, in which (A), (B) and (C) contained therein are in inhalable form. 3. A capsule according to claim 2, in which the pharmaceutical composition contained therein is a dry powder formulation. 4. A capsule according to claim 3 that contains a daily dose of (A) and a daily dose of (B). 5. A capsule according to claim 4, in which the daily dose of (A) is from 1 .mu.g to 5000 .mu.g. 6. A capsule according to claim 1, in which (A) is (R)-5-[2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-1H-quin- olin-2-one maleate. 7. A capsule according to claim 5, in which (A) is (R)-5-[2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-1H-quin- olin-2-one maleate. 8. A capsule according to claim 1, in which (B) is selected from the group consisting of ipratropium bromide, oxitropium bromide and tiotropium bromide. 9. A capsule according to claim 8, in which (B) is tiotropium bromide. 10. A capsule according to claim 4, in which (B) is selected from the group consisting of ipratropium bromide, oxitropium bromide and tiotropium bromide. 11. A capsule according to claim 10, in which (B) is tiotropium bromide. 12. A capsule according to claim 1, in which (A) is (R)-5-[2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-1H-quin- olin-2-one maleate and (B) is selected from the group consisting of ipratropium bromide, oxitropium bromide and tiotropium bromide. 13. A capsule according to claim 1, in which (A) is (R)-5-[2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-1H-quin- olin-2-one maleate and (B) is tiotropium bromide. |